Published in J Clin Invest on September 01, 2007
Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell (2009) 14.51
Targeting the mTOR signaling network for cancer therapy. J Clin Oncol (2009) 4.52
Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature (2012) 3.13
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest (2008) 2.40
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A (2013) 2.29
Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell (2012) 2.19
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
Translational control in cancer etiology. Cold Spring Harb Perspect Biol (2013) 1.71
Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA (2008) 1.69
The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol (2011) 1.54
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A (2013) 1.53
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood (2011) 1.43
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood (2015) 1.42
Postnatal deamidation of 4E-BP2 in brain enhances its association with raptor and alters kinetics of excitatory synaptic transmission. Mol Cell (2010) 1.38
Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A (2010) 1.30
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther (2008) 1.26
Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res (2015) 1.23
Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther (2009) 1.21
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res (2011) 1.20
Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma (2010) 1.20
Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget (2012) 1.17
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia (2010) 1.16
Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood (2010) 1.15
Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer (2011) 1.14
mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition. Mol Cell Biol (2009) 1.13
Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood (2013) 1.13
Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep (2012) 1.12
Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest (2012) 1.11
Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res (2009) 1.09
Targeting translation dependence in cancer. Oncotarget (2011) 1.09
Versatility of RNA-Binding Proteins in Cancer. Comp Funct Genomics (2012) 1.08
Sumoylation of eIF4E activates mRNA translation. EMBO Rep (2010) 1.07
Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect Biol (2012) 1.04
The oncogene eIF4E: using biochemical insights to target cancer. J Interferon Cytokine Res (2013) 1.03
Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res (2009) 1.02
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther (2012) 1.02
Individual and combined soy isoflavones exert differential effects on metastatic cancer progression. Clin Exp Metastasis (2010) 1.02
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res (2012) 1.01
DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs. Proc Natl Acad Sci U S A (2012) 1.00
eIF4F suppression in breast cancer affects maintenance and progression. Oncogene (2012) 0.99
Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol (2009) 0.99
Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. Br J Cancer (2009) 0.95
Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol (2015) 0.94
Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res (2013) 0.94
Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail. Oncotarget (2014) 0.94
Taking aim at translation for tumor therapy. J Clin Invest (2007) 0.94
Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death Dis (2012) 0.94
Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer. J Oncol (2009) 0.93
New frontiers in translational control of the cancer genome. Nat Rev Cancer (2016) 0.92
Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol (2011) 0.91
Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence. Oncotarget (2011) 0.91
Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation. Mol Cell Biol (2013) 0.91
Noncytotoxic inhibition of viral infection through eIF4F-independent suppression of translation by 4EGi-1. J Virol (2010) 0.91
Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation. J Cell Commun Signal (2012) 0.90
Translational regulation in nutrigenomics. Adv Nutr (2011) 0.90
Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. PLoS Genet (2014) 0.90
Small-Molecule targeting of translation initiation for cancer therapy. Oncotarget (2013) 0.89
The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br J Cancer (2012) 0.89
Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol (2012) 0.89
The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia. Leukemia (2013) 0.89
Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev Res (Phila) (2010) 0.88
HDAC2 promotes eIF4E sumoylation and activates mRNA translation gene specifically. J Biol Chem (2010) 0.88
First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget (2014) 0.88
Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation. Mol Cancer Ther (2012) 0.87
Signalling to eIF4E in cancer. Biochem Soc Trans (2015) 0.86
Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation. Int J Oncol (2011) 0.85
Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun (2008) 0.85
Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide. PLoS One (2013) 0.85
eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion. J Invest Dermatol (2015) 0.84
The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled. Immunol Rev (2015) 0.84
Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int J Mol Sci (2013) 0.84
Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate. Biochem Biophys Res Commun (2013) 0.84
Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells. Cancer Gene Ther (2015) 0.83
Increased susceptibility of breast cancer cells to stress mediated inhibition of protein synthesis. Cancer Res (2008) 0.83
Localized Rho GTPase activation regulates RNA dynamics and compartmentalization in tumor cell protrusions. J Biol Chem (2008) 0.83
MicroRNAs 125a and 125b inhibit ovarian cancer cells through post-transcriptional inactivation of EIF4EBP1. Oncotarget (2016) 0.83
Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC. J Thorac Oncol (2013) 0.82
Reduced eukaryotic initiation factor 2Bepsilon-subunit expression suppresses the transformed phenotype of cells overexpressing the protein. Cancer Res (2008) 0.82
The soy isoflavone equol may increase cancer malignancy via up-regulation of eukaryotic protein synthesis initiation factor eIF4G. J Biol Chem (2012) 0.81
Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol (2010) 0.80
Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget (2015) 0.80
Expression of human eukaryotic initiation factor 3f oscillates with cell cycle in A549 cells and is essential for cell viability. Cell Div (2010) 0.80
Enzymatic synthesis of RNAs capped with nucleotide analogues reveals the molecular basis for substrate selectivity of RNA capping enzyme: impacts on RNA metabolism. PLoS One (2013) 0.79
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds. Chem Biol (2015) 0.79
Requirement for the eIF4E binding proteins for the synergistic down-regulation of protein synthesis by hypertonic conditions and mTOR inhibition. PLoS One (2013) 0.79
New insights into 4E-BP1-regulated translation in cancer progression and metastasis. Cancer Cell Microenviron (2015) 0.79
Metastasis Research Society-American Association For Cancer Research Joint Conference on Metastasis. Cancer Res (2008) 0.79
Axonal cap-dependent translation regulates presynaptic p35. Dev Neurobiol (2013) 0.79
Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery. ACS Nano (2017) 0.79
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers (Basel) (2012) 0.78
Inhibition of translation by cytotrienin A--a member of the ansamycin family. RNA (2010) 0.78
Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes. Nucleic Acids Res (2014) 0.78
Knockdown of eukaryotic translation initiation factor 4E suppresses cell growth and invasion, and induces apoptosis and cell cycle arrest in a human lung adenocarcinoma cell line. Mol Med Rep (2015) 0.78
Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. Invest New Drugs (2014) 0.78
Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A. Translation (Austin) (2016) 0.78
Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI. Lab Invest (2016) 0.77
Hepatic RNA Interference: Delivery by Synthetic Vectors. Drug Deliv Transl Res (2014) 0.77
Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia (2014) 0.77
Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma. Br J Cancer (2016) 0.77
Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. Mol Cancer Ther (2016) 0.77
Genes expressed in human tumor endothelium. Science (2000) 10.75
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature (1990) 7.74
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev (1998) 6.89
eIF-4E expression and its role in malignancies and metastases. Oncogene (2004) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
eIF4E--from translation to transformation. Oncogene (2004) 3.78
Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A (1996) 3.55
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A (2000) 3.40
Akt-regulated pathways in prostate cancer. Oncogene (2005) 3.35
Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91
Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol (1993) 2.75
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One (2007) 2.35
Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem (1995) 2.09
The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene (1996) 2.04
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem (2000) 1.91
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol (2006) 1.90
Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther (2001) 1.73
Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res (1994) 1.73
An in vitro model of angiogenesis: basic features. Angiogenesis (1999) 1.71
Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res (2004) 1.65
Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev (1992) 1.62
Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol (1996) 1.60
Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene (2004) 1.58
Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 1.54
Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene (1997) 1.50
Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res (2000) 1.49
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol (2000) 1.43
Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem (2002) 1.35
Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer (1993) 1.35
Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res (2006) 1.27
Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer (1995) 1.22
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci (2004) 1.20
Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol (1998) 1.15
Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol (2000) 1.15
Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope (2000) 1.13
Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp Cell Res (1991) 1.00
Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J Biol Chem (2004) 0.96
Translation of ODC mRNA and polyamine transport are suppressed in ras-transformed CREF cells by depleting translation initiation factor 4E. Biochem Biophys Res Commun (1997) 0.96
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell (2009) 11.36
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth (2009) 8.28
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
The carbon balance of terrestrial ecosystems in China. Nature (2009) 6.84
MicroRNA-143 regulates adipocyte differentiation. J Biol Chem (2004) 6.78
Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys (2006) 6.51
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell (2009) 5.49
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Aging, progenitor cell exhaustion, and atherosclerosis. Circulation (2003) 5.19
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab (2007) 4.16
Identification of an organelle receptor for myosin-Va. Nat Cell Biol (2002) 4.06
Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell (2013) 3.81
BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet (2006) 3.79
Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med (2008) 3.69
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med (2007) 3.61
Mobile interspersed repeats are major structural variants in the human genome. Cell (2010) 3.60
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med (2008) 3.36
Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet (2012) 3.34
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem (2002) 3.32
Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet (2006) 3.27
Modeling quantitative trait Loci and interpretation of models. Genetics (2005) 3.15
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res (2004) 3.11
Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint. Mol Cell Biol (2004) 3.06
Transcription factor KLF2 regulates the migration of naive T cells by restricting chemokine receptor expression patterns. Nat Immunol (2008) 3.05
Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res (2008) 3.02
Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell (2006) 3.01
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest (2008) 2.95
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res (2004) 2.94
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
FARP2 triggers signals for Sema3A-mediated axonal repulsion. Nat Neurosci (2005) 2.87
Melamine related bilateral renal calculi in 50 children: single center experience in clinical diagnosis and treatment. J Urol (2010) 2.83
Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell (2013) 2.83
Fiber formation across the bacterial outer membrane by the chaperone/usher pathway. Cell (2008) 2.69
Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int (2003) 2.69
Improved rapid amplification of cDNA ends (RACE) for mapping both the 5' and 3' terminal sequences of paramyxovirus genomes. J Virol Methods (2005) 2.66
Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet (2008) 2.65
Cell wall stress responses in Bacillus subtilis: the regulatory network of the bacitracin stimulon. Mol Microbiol (2003) 2.62
Isolation of spermatozoa with low levels of fragmented DNA with the use of flow cytometry and sorting. Fertil Steril (2013) 2.60
Global analysis of the Bacillus subtilis Fur regulon and the iron starvation stimulon. Mol Microbiol (2002) 2.55
A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol (2012) 2.54
UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell (2006) 2.51
Gene expression analysis reveals chemical-specific profiles. Toxicol Sci (2002) 2.50
C. elegans screen identifies autophagy genes specific to multicellular organisms. Cell (2010) 2.50
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics (2004) 2.49
H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet (2012) 2.47
Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis (2004) 2.47
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Guidance of myocardial patterning in cardiac development by Sema6D reverse signalling. Nat Cell Biol (2004) 2.39
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood (2002) 2.38
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol (2011) 2.37
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
SEPA-1 mediates the specific recognition and degradation of P granule components by autophagy in C. elegans. Cell (2009) 2.35
Antibiotics that inhibit cell wall biosynthesis induce expression of the Bacillus subtilis sigma(W) and sigma(M) regulons. Mol Microbiol (2002) 2.32
Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A (2005) 2.31
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis (2008) 2.31
Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res (2009) 2.24
Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. J Occup Environ Med (2006) 2.24
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. Genes Dev (2004) 2.22
Histone demethylase UTX-1 regulates C. elegans life span by targeting the insulin/IGF-1 signaling pathway. Cell Metab (2011) 2.22
Exploring techniques for vision based human activity recognition: methods, systems, and evaluation. Sensors (Basel) (2013) 2.22
Differential control over postganglionic neurons in rat cardiac ganglia by NA and DmnX neurons: anatomical evidence. Am J Physiol Regul Integr Comp Physiol (2003) 2.20
Crystal structure of the heterodimeric CLOCK:BMAL1 transcriptional activator complex. Science (2012) 2.20
Outcomes of deep anterior lamellar keratoplasty using the big-bubble technique in various corneal diseases. Am J Ophthalmol (2012) 2.20
Ascaris suum draft genome. Nature (2011) 2.16
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol Cell (2008) 2.15
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Evaluation of terrestrial carbon cycle models for their response to climate variability and to CO2 trends. Glob Chang Biol (2013) 2.13
PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate (2011) 2.13
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
Immune-related microRNAs are abundant in breast milk exosomes. Int J Biol Sci (2011) 2.11
Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A (2008) 2.09
Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med (2011) 2.08
Comprehensive analysis of donor-site morbidity in abdominally based free flap breast reconstruction. Plast Reconstr Surg (2013) 2.07
Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Kidney Int (2013) 2.05
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
Time trends and familial risks in squamous cell carcinoma of the skin. Arch Dermatol (2003) 2.04
Regional deposition of mometasone furoate nasal spray suspension in humans. Allergy Asthma Proc (2015) 2.04
Exploring the engine of anthropogenic iron cycles. Proc Natl Acad Sci U S A (2006) 2.03